Charles River Laboratories
Charles River Laboratories International, Inc. (NYSE: CRL) provides non-clinical drug research and development services, research models, and products and services that support biopharmaceutical manufacturing and quality testing. Its customers include pharmaceutical and biotechnology companies, chemical and… From the company’s description.
In fiscal 2025, Charles River Laboratories reported revenue of $4.02B, down 0.9% from fiscal 2024, and a net loss of $142.16M. Its operating margin was 0.6%, and operations generated $737.65M in cash. Over the twelve months to Jun 27, 2026, revenue was $4.00B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Charles River Laboratories does
In the company’s own words
Charles River Laboratories International, Inc. (NYSE: CRL) provides non-clinical drug research and development services, research models, and products and services that support biopharmaceutical manufacturing and quality testing. Its customers include pharmaceutical and biotechnology companies, chemical and consumer-product manufacturers, contract research organizations, academic institutions, hospitals, and government agencies. The company operates three reportable segments: Research Models and Services, which supplies purpose-bred research models and related services and represented 21.1% of 2025 revenue; Discovery and Safety Assessment, which provides drug discovery, bioanalytical, and regulatory safety testing services and represented 59.8%; and Manufacturing Solutions, which provides microbial testing, biologics testing, and contract development and manufacturing and represented 19.1%. Its brands include Endosafe, Celsis, and Accugenix in microbial testing, and CRADL research facilities. Charles River began operating in 1947 and has since developed a broader portfolio spanning early drug research through manufacturing support. In 2025, revenue was $4.0 billion, and the company operated at more than 120 sites in over 20 countries. Its website is www.criver.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Professional Services
- Headquarters
- WILMINGTON, MA
- Fiscal year end
- December
- CIK
- 1100682
- SIC
- 8731
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Charles River Laboratories — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Charles River Laboratories · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Charles River Laboratories’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Charles River Laboratories’s bonds, as funds hold them
Funds report holding 3 issues of Charles River Laboratories’s debt, $484.81M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.00%, maturing 2028 to 2031.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Charles River Laboratories and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Charles River Laboratories's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Charles River Laboratories's last four quarterly filings that the numbers alone won't show?”